Alpha-galactosidase A - Research Corporation Technologies

Drug Profile

Alpha-galactosidase A - Research Corporation Technologies

Alternative Names: Alpha-galactosidase - Research Corporation Technologies; Arginosuccinate lyase; Beta-glucosidase

Latest Information Update: 27 Nov 1998

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Research Corporation Technologies
  • Developer Orphan Medical; Research Corporation Technologies
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fabry's disease

Most Recent Events

  • 27 Nov 1998 Discontinued-Preclinical for Fabry's disease in USA (Unknown route)
  • 13 May 1997 Orphan Medical is a licensee for α-galactosidase in the USA
  • 13 May 1997 Preclinical development for Fabry's disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top